Aktis Oncology, Inc.
AKTS Nasdaq
SEC CIK 2035832
Follow Aktis Oncology
Weekly email: filings, results
Revenue, last quarter
$3.9M
+147.3% vs same quarter last year
Net income
−$29.9M
−92.7% vs same quarter last year
EPS, diluted
−$0.54
+97.2% vs same quarter last year
Operating cash flow
−$26.1M
−71.1% vs same quarter last year
Source: SEC XBRL filings · latest filing